Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. Financials
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Delayed Swiss Exchange  -  11:31:24 2023-01-27 am EST
50.80 CHF   -1.74%
01/24Basilea Pharmaceutica : Updated January 24, 2023
PU
01/24Basilea Forecasts Return to Profit in FY22 Over Anti-infectives Focus
MT
01/24Basilea reports preliminary operating profit for 2022, significantly above guidance
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 503574485606606-
Enterprise Value (EV)1 540647553696657605
P/E ratio -22,5x-37,2x-70,6x-36,5x41,8x19,4x
Yield ------
Capitalization / Revenue 3,74x4,50x3,27x5,06x4,58x3,92x
EV / Revenue 4,02x5,07x3,73x5,81x4,97x3,91x
EV / EBITDA -34,7x-29,3x287x-165x23,6x12,5x
Enterprise Value (EV) / FCF -8,40x-11,5x-16,8x-99,4x16,7x16,0x
FCF Yield -11,9%-8,72%-5,94%-1,01%5,98%6,27%
Price to Book -5,43x-5,36x----
Nbr of stocks (in thousands) 10 73710 80311 84411 93511 935-
Reference price (CHF) 46,953,240,950,850,850,8
Announcement Date 02/18/202002/16/202102/15/2022---
1 CHF in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 134128148120132155
EBITDA1 -15,6-22,11,93-4,2127,848,6
Operating profit (EBIT)1 -17,2-8,221,20-4,8026,446,5
Operating Margin -12,8%-6,44%0,81%-4,01%19,9%30,0%
Pre-Tax Profit (EBT)1 -22,4-14,7-6,80-15,119,043,1
Net income1 -22,4-14,7-6,80-15,117,238,8
Net margin -16,7%-11,5%-4,59%-12,6%13,0%25,1%
EPS2 -2,08-1,43-0,58-1,391,212,62
Free Cash Flow1 -64,2-56,4-32,9-7,0039,337,9
FCF margin -47,8%-44,2%-22,2%-5,84%29,7%24,5%
FCF Conversion 413%256%-1 706%166%141%78,1%
Dividend per Share ------
Announcement Date 02/18/202002/16/202102/15/2022---
1 CHF in Million
2 CHF
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2
Net sales1 54,293,958,656,260,564,5
EBITDA ------
Operating profit (EBIT)1 -15,416,6-9,04-7,85--
Operating Margin -28,4%17,7%-15,4%-14,0%--
Pre-Tax Profit (EBT)1 -19,913,1-12,2-9,80--
Net income1 -19,913,1-12,2-9,80--
Net margin -36,7%14,0%-20,8%-17,4%--
EPS2 -1,841,26-1,03-0,82-0,32-0,09
Dividend per Share ------
Announcement Date 08/17/202102/15/202208/16/2022---
1 CHF in Million
2 CHF
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 36,772,468,189,750,9-
Net Cash position1 -----1,00
Leverage (Debt / EBITDA) -2,36x-3,28x35,4x-21,3x1,83x-0,02x
Free Cash Flow1 -64,2-56,4-32,9-7,0039,337,9
ROE (Net Profit / Equities) ----104%49,0%
Shareholders' equity1 ----16,679,2
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share -8,63-9,93----
Cash Flow per Share ------
Capex1 0,402,270,861,311,431,65
Capex / Sales 0,30%1,77%0,58%1,09%1,08%1,07%
Announcement Date 02/18/202002/16/202102/15/2022---
1 CHF in Million
Previous periodNext period
Estimates
Key data
Capitalization (CHF) 606 285 096
Capitalization (USD) 658 247 124
Net sales (CHF) 148 100 000
Net sales (USD) 160 792 999
Number of employees 177
Sales / Employee (CHF) 836 723
Sales / Employee (USD) 908 435
Free-Float 88,1%
Free-Float capitalization (CHF) 534 114 579
Free-Float capitalization (USD) 579 891 189
Avg. Exchange 20 sessions (CHF) 2 305 172
Avg. Exchange 20 sessions (USD) 2 502 738
Average Daily Capital Traded 0,38%
EPS & Dividend
Change in Enterprise Value/EBITDA